A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer

Nanjing Leads Biolabs

Status and phase: Not yet enrolling; Phase 2; Phase 1

Conditions: Triple Negative Breast Cancer

Treatments: Drug: Toripalimab Injection; Drug: LBL-024 for Injection; Drug: albumin-bound Paclitaxel injection

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT07281976

LBL-024-CN005

Details and patient eligibility

About

This trial is an open-label, multicenter phase Ib/II clinical study to evaluate the efficacy and safety of LBL-024 monotherapy or in combination with albumin-bound paclitaxel in patients with recurrent or metastatic triple negative breast cancer(TNBC).

Full description

The trial was divided into two phases.

Stage I (Phase Ib):

Part A: Monotherapy Period:In the phase Ib Part A monotherapy period, a small number of TNBC patients were planned to be enrolled to receive LBL-024 monotherapy.The safety, tolerability, and preliminary efficacy of LBL-024 monotherapy in this population will be assessed by the sponsor and investigator in combination.

Part B: Combination Drug Safety Run-In Period:If the safety and tolerability are good and there is preliminary efficacy in Part A,The investigator discussed with the sponsor to decide whether to continue the study in Part B of Phase Ib.Part B is designed to enroll a small number of TNBC patients to receive LBL-024 combination therapy.

Stage II (Phase II) ： If the safety and tolerability are good and there is preliminary efficacy in the first stage,The investigator discusses with the sponsor to decide whether to continue the co-administration expansion study, continue to enroll TNBC patients, and using a randomized, open, positive control trial design.

This study will enroll up to 220 subjects.

Enrollment: 220 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Agree to follow the trial treatment regimen, visit schedule, laboratory test, and other requirements of the protocol, and voluntarily enroll in the study and sign the written informed consent.
2. At the time of signing the informed consent form, the age was ≥ 18 years old.
3. The Eastern Cooperative Oncology Group's physical status scoring standard (ECOG) is 0~1.
4. The expected survival time is at least 12 weeks.
5. According to the evaluation of RECIST 1.1 （Response Evaluation Criteria in Solid Tumours），the subjects enrolled have at least one measurable lesion.
6. Females of childbearing age are willing to take highly effective contraceptive measures From the signing of the informed consent form to within 6 months after the last administration of the trial drug; Women of childbearing age must have a negative pregnancy test within 7 days before the first trial drug is administered.Male patients are willing to take highly effective contraceptive measures From the signing of the informed consent form to within 6 months after the last administration of the trial drug,and do not donate sperm during this period.

Exclusion criteria

1. Use of immunomodulatory drugs within 2 weeks prior to first dose of study drug.

2. Patients who received live vaccination within 4 weeks before the first dose of study drug or who are scheduled to receive live vaccination during the study treatment period and within 4 weeks after the last dose.

3. Patients with clinically uncontrolled pleural effusion, peritoneal effusion, or pericardial effusion.

4. Active infection within 2 weeks prior to first dose of study drug.

5. Active infectious disease.

6. Women with plans for pregnancy,Or women who are pregnant or breastfeeding.

7. Active hepatitis B or active hepatitis C.

8. History of mental illness (interfering with understanding or giving informed consent), drug abuse, alcoholism, or drug addiction.

9. The investigator believes that the subject has other conditions that may affect compliance or are not suitable for participating in this study.

   -

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

220 participants in 2 patient groups

LBL-024 + albumin-bound paclitaxel

Experimental group

Description:

Experimental group： LBL-024 + albumin-bound paclitaxel. Intravenous infusion.

Treatment:

Drug: albumin-bound Paclitaxel injection

Drug: LBL-024 for Injection

Toripalimab + albumin-bound paclitaxel/albumin-bound paclitaxel

Active Comparator group

Description:

control group： Toripalimab + albumin-bound paclitaxel or albumin-bound paclitaxel. Intravenous infusion.

Treatment:

Drug: albumin-bound Paclitaxel injection

Drug: Toripalimab Injection